| 84.8476 -0.272 (-0.32%) | 10-15 12:19 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 101.11 | 1-year : | 118.1 |
| Resists | First : | 86.56 | Second : | 101.11 |
| Pivot price | 82.13 |
|||
| Supports | First : | 78.12 | Second : | 72.9 |
| MAs | MA(5) : | 84.76  |
MA(20) : | 80.71 |
| MA(100) : | 75.7 |
MA(250) : | 72.34 |
|
| MACD | MACD : | 1.9 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 86.7 |
D(3) : | 86.4 |
| RSI | RSI(14): 63.2 |
|||
| 52-week | High : | 86.56 | Low : | 61.24 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AZN ] has closed below upper band by 36.6%. Bollinger Bands are 148.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 85.36 - 85.93 | 85.93 - 86.44 |
| Low: | 82.88 - 83.61 | 83.61 - 84.27 |
| Close: | 84 - 85.14 | 85.14 - 86.18 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Wed, 15 Oct 2025
AstraZeneca (AZN) Expands Coppell Facility to Boost Lokelma Prod - GuruFocus
Wed, 15 Oct 2025
$445M expansion: AstraZeneca doubles Lokelma production at Coppell, adds 9,000 sq ft - Stock Titan
Tue, 14 Oct 2025
UBS Keeps Their Buy Rating on AstraZeneca (AZN) - The Globe and Mail
Mon, 13 Oct 2025
AstraZeneca PLC (AZN) Stock Analysis: 6.2% Potential Upside Fuels Investor Interest - DirectorsTalk Interviews
Sat, 11 Oct 2025
AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts - ts2.tech
Sat, 11 Oct 2025
Mengis Capital Management Inc. Grows Stake in AstraZeneca PLC $AZN - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 3,100 (M) |
| Shares Float | 1,540 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 16.7 (%) |
| Shares Short | 5,460 (K) |
| Shares Short P.Month | 7,770 (K) |
| EPS | 2.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 28.85 |
| Profit Margin | 14.6 % |
| Operating Margin | 24.1 % |
| Return on Assets (ttm) | 8.2 % |
| Return on Equity (ttm) | 19.6 % |
| Qtrly Rev. Growth | 11.6 % |
| Gross Profit (p.s.) | 14.99 |
| Sales Per Share | 18.22 |
| EBITDA (p.s.) | 6.17 |
| Qtrly Earnings Growth | 27.6 % |
| Operating Cash Flow | 13,390 (M) |
| Levered Free Cash Flow | 8,970 (M) |
| PE Ratio | 31.93 |
| PEG Ratio | 0 |
| Price to Book value | 2.93 |
| Price to Sales | 4.64 |
| Price to Cash Flow | 19.59 |
| Dividend | 0.5 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|